The Outcome of Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension during the COVID-19 Pandemic-Reference-Cited by-同舟云学术

The Outcome of Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension during the COVID-19 Pandemic

Published:2023-03-23 Issue:2 Volume:22 Page:60-64
ISSN:1535-2811
Container-title:Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine
language:en
Short-container-title:

Author:

Serati Alireza¹,Keshmiri Mohammad Sadegh¹,Shafaghi Shadi¹,Mohammad Majid Malek²,Kashani Babak Sharif¹,Naghashzadeh Farah¹,Mohamadifar Arezoo¹,Shafaghi Masoud³,Noorali Sima¹,Hajimoradi Maryam¹,Astani Bahamin¹,Aghdasi Sina¹,Riahi Mahsa¹,Alavi Sima⁴,Malek Rayka⁵,Movahed Mohammad Reza⁶⁷

Affiliation:

1. From the *Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

2. Tracheal Diseases Research Center (TDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

3. Strategic Planning and Executive Office Manager of International Federation of Inventors’ Associations-IFIA, Geneva, Switzerland

4. Institute of Technology Development of Canada, Vancouver, Canada

5. Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran

6. University of Arizona Sarver Heart Center, Tucson, AZ

7. University of Arizona, Phoenix, AZ.

Abstract

Background: The coronavirus 2019 (COVID-19) has affected the lives of many people worldwide. Patients with chronic underlying morbidities are vulnerable to get the severe form of the infection. The goal of this study was to evaluate the outcome of patients with pulmonary arterial hypertension during the COVID-19 pandemic in Iran. Methods: This cross-sectional study was conducted at a large tertiary center for pulmonary artery hypertension (PAH) patients. The primary end point was the prevalence of SARS-CoV-2 infection in PAH patients. The secondary end points were investigating the severity and mortality of COVID-19 infection in PAH patients during the COVID-19 pandemic. Results: Totally 75 patients were enrolled in the study from December 2019 to October 2021 and 64% were female. The mean ± SD age was 49 ± 16 years. The prevalence of COVID-19 in PAH/chronic thromboembolic pulmonary hypertension patients was 44%. About 66.7% of patients had comorbidities, which was a prognostic factor for COVID-19 infection in PAH patients (P < 0.001). Fifty-six percent of infected patients were asymptomatic. The most reported symptoms in symptomatic patients were fever (28%) and malaise (29%). Twelve percent of patients were admitted with severe symptoms. The mortality rate in infected individuals was 3.7%. Conclusions: COVID-19 infection in PAH/chronic thromboembolic pulmonary hypertension patients seems to be associated with high mortality and morbidity. More scientific proof is needed to clarify different aspect of COVID-19 infection in this population.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference15 articles.

1. Effect of coronavirus disease 2019 in pulmonary circulation. The particular scenario of precapillary pulmonary hypertension.;Nuche;Diagnostics (Basel, Switzerland),2020

2. Pulmonary arterial hypertension and COVID-19.;Avellanas Chavala;Med Intensiva,2020

3. COVID-19 and pulmonary arterial hypertension: early data and many questions.;Farha;Ann Am Thorac Soc,2020

4. Pulmonary Arterial hypertension: diagnosis, treatment, and novel advances.;Maron;Am J Respir Crit Care Med,2021

5. Epidemiology, pathogenesis, and clinical approach in group 5 pulmonary hypertension.;Al-Qadi;Front Med,2020